KEY OPINION LEADERS
Medical education agency
promoting co-construction with all stakeholders
to better address the issues of health actors.
THE FLOOR TO THE KOLs
PROFESSOR MARKUS SCHLAICH
Renal Physician & Hypertension Specialist
from University of Western Australia
talks about KPL's role in The “SIRA Treatment Recommendation and Action In Global management of HyperTension” (STRAIGHT) program.
The aim of this international project was to evaluate the hypertension management strategies in 6 selected countries with high prescription rates of SIRAs (Arabian states including KSA and UAE, India, Lebanon, Russia, Saudi Arabia, South Africa) to better understand the rationale and indications for their use in a real-life setting
in order to draft an Expert Consensus on the SIRA class position in the treatment of hypertensive patients not normalized by the monotherapy and having specific profiles: metabolic syndrome, overweight or postmenopausal women. And then to submitt an international publication about the place of the SIRA class in the guidelines for these subpopulations.
PROFESSOR VLAD RATZIU
MD, Professor of Hepatology
at the Pitié-Salpêtrière Hospital, Paris
talks about KPL's role in The "Pop Next Project”.
Non-alcoholic steatohepatitis (NASH), characterized by steatosis, lobular inflammation, fibrosis and hepato-cellular ballooning, is set to become the first indication for liver transplantation in the US, in upcoming years.
The POP Next project, for "Patterns Of Practice in Nash and EXpectations for Therapies - Intercontinental survey" aims to publish an expert position paper based on the current and future management of patients with nonalcoholic steatohepatitis. This intercontinental survey involves liver specialists from 8 countries: France, Germany, Hong Kong, Italy, Romania, Spain, UK and USA in order to obtain a comprehensive understanding of NASH management, taking account of the diversity of the disease and health care systems.
PROFESSOR PAUL VALENSI
MD, Professor of Diabetology
at the Jean Verdier Hospital, Paris
Talks about KPL's role in the PADDIA/CADDIA project.
Peripheral artery disease (PAD) and coronary artery disease (CAD) screening and management are suboptimal in patients with diabetes, even though such patients have an increased risk of ischemic events. Currently, no exhaustive guidelines are available to manage these patients.
The PADDIA (Peripheral Artery Disease in DIAbetic patients) / CADDIA (Coronary Artery Disease in DIAbetic patients) project, endorsed by Diabetes & Cardiovascular Disease study group, and involving 7 countries (Austria, Belgium, France, Germany, Italy, Netherlands and UK) aims to establish current practice for PAD & CAD disease management in people with diabetes, and to develop an expert position for improvement.
Business Development & Innovation Manager
Phone: +33 (0) 182 732 198
7 rue des Filles du Calvaire, 75003 Paris, FRANCE